ReDiscover-2: Currently Enrolling Patients With PIK3CA-Mutated Advanced Breast Cancer

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Sammons, MD Despite advances in the treatment of HR-positive HER2-negative advanced breast cancer, patients with PIK3CA -mutated disease who progress after a CDK4/6 inhibitor still face limited effective and tolerable treatment options. 1 This unmet need has fueled interest in zovegalisib (formerly RLY-2608), a next generation,…